IB IBBQ iShares Biotechnology ETF Loading... : Bullish and Bearish Analyst Opinions

The data-center industry has become large and dynamic enough to create investment opportunity across many parts of the value chain, including development projects, stabilized assets, GPUs, and fiber, with capital demand at unprecedented levels.

The Korean biotech/healthcare sector has been heavily sold off and is deeply underperforming KOSPI and KOSDAQ. The sell-off is driven by temporary trust issues (disclosure scandals at Alteogen and Samchundang Pharm) and fund outflows to semiconductor levered products, not by fundamental deterioration. Sector fundamentals are strong with 16% revenue growth and rising R&D output. Multiple H2 catalysts—including the 150 trillion won government growth fund targeting biotech, big pharma licensing deals due to patent expiries, and upcoming clinical data—support a rebound from deeply depressed levels.